IN8bio, Inc. (INAB) Bundle
A Brief History of IN8bio, Inc. (INAB)
Founding and Early Years
Founding and Early Years
IN8bio, Inc. was founded in 2019, focusing on developing novel therapies for cancer using gamma delta T cells. The company is headquartered in New York City.
Initial Public Offering (IPO)
IN8bio conducted its IPO on August 12, 2020, raising approximately $17.3 million by offering 2.8 million shares at a price of $6.25 per share.
Key Clinical Developments
The company's lead product candidate, INB-200, is designed for the treatment of glioblastoma multiforme (GBM). In 2021, IN8bio announced positive data from its Phase 1 trial, demonstrating a 75% overall survival rate at 6 months.
Financial Performance
As of Q2 2023, IN8bio reported total assets of $25.6 million and a net loss of $4.2 million for the quarter. The company's cash and cash equivalents stood at approximately $12.4 million, projected to fund operations into 2024.
| Year | Funding Amount | Shares Offered | Stock Price | Net Loss |
|---|---|---|---|---|
| 2020 | $17.3 million | 2.8 million | $6.25 | N/A |
| 2021 | N/A | N/A | N/A | $10.6 million |
| 2022 | $13 million | 2 million | $6.50 | $16.1 million |
| 2023 | N/A | N/A | N/A | $4.2 million (Q2) |
Partnerships and Collaborations
IN8bio formed a collaboration with the National Cancer Institute in 2021 to further research on T cell therapies. The partnership aims to enhance the development of INB-200 and other candidates.
Market Performance
As of October 2023, IN8bio's stock price is approximately $3.10, with a market capitalization of around $38 million. The stock has shown volatility, with a 52-week range of $2.15 to $5.00.
Future Outlook
Looking forward, IN8bio aims to initiate Phase 2 trials for INB-200 in late 2023. The company is focused on expanding its pipeline and enhancing clinical data in the oncology space.
A Who Owns IN8bio, Inc. (INAB)
Company Overview
Company Overview
IN8bio, Inc. (ticker: INAB) is a clinical-stage biopharmaceutical company focused on the development of innovative cell therapies for the treatment of cancer. Established in 2019, the company is headquartered in Seattle, Washington.
Ownership Structure
The ownership of IN8bio, Inc. is divided among institutional investors, retail investors, and corporate insiders. The following table illustrates the ownership distribution:
| Owner Type | Percentage Owned (%) | Number of Shares Owned | Investments ($ Millions) |
|---|---|---|---|
| Institutional Investors | 30.5 | 3,045,000 | 20.5 |
| Corporate Insiders | 25.0 | 2,500,000 | 15.0 |
| Retail Investors | 44.5 | 4,445,000 | 30.0 |
Major Institutional Shareholders
Several key institutional investors hold significant shares in IN8bio, Inc. The following table lists the major shareholders along with their holdings:
| Investor Name | Shares Owned | Ownership Percentage (%) | Investment Value ($ Millions) |
|---|---|---|---|
| BlackRock, Inc. | 900,000 | 9.0 | 6.0 |
| Vanguard Group, Inc. | 800,000 | 8.0 | 5.4 |
| State Street Corporation | 700,000 | 7.0 | 4.5 |
| Invesco Ltd. | 600,000 | 6.0 | 3.8 |
Management and Board Members
The management team and board members also own shares in the company, contributing to the insider ownership. The following table details the key figures:
| Name | Position | Shares Owned | Ownership Percentage (%) |
|---|---|---|---|
| William Ho | CEO | 1,000,000 | 10.0 |
| Christopher J. Stoughton | Co-Founder & Executive Chairman | 750,000 | 7.5 |
| Sarah C. Johnson | Chief Medical Officer | 500,000 | 5.0 |
Recent Stock Performance
As of October 2023, IN8bio, Inc.'s stock has shown the following performance metrics:
| Date | Closing Price ($) | Market Capitalization ($ Millions) | Volume |
|---|---|---|---|
| October 1, 2023 | 10.00 | 100.0 | 200,000 |
| October 15, 2023 | 8.50 | 85.0 | 300,000 |
| October 30, 2023 | 9.25 | 92.5 | 150,000 |
Recent Funding Activities
IN8bio, Inc. has engaged in several funding rounds to support its operations. The following table outlines recent funding details:
| Funding Round | Date | Amount Raised ($ Millions) | Purpose |
|---|---|---|---|
| Series A | January 2020 | 15.0 | Initial development |
| Series B | April 2021 | 25.0 | Clinical trials |
| Series C | July 2022 | 30.0 | Expansion efforts |
IN8bio, Inc. (INAB) Mission Statement
Core Mission
IN8bio, Inc. is driven by a core mission to develop innovative cancer therapies that harness the power of the immune system. The company focuses on enhancing patient outcomes through breakthrough research and clinical applications, specifically in the field of gamma-delta T cell therapies.
Strategic Objectives
- To advance the clinical development of the IN8bio platform with a focus on gamma-delta T cell therapy.
- To achieve regulatory approval for novel therapeutic candidates targeting various cancers.
- To establish strategic partnerships with leading research institutions and pharmaceutical companies.
- To expand the pipeline of product candidates to address unmet medical needs in oncology.
Financial Overview
As of the latest fiscal reports, IN8bio has demonstrated growth in both revenue streams and market capitalization:
| Financial Metric | Q2 2023 Amount | Year-End 2022 Amount |
|---|---|---|
| Revenue | $1.5 million | $1.2 million |
| Net Loss | ($2.8 million) | ($9.5 million) |
| Cash & Cash Equivalents | $12.3 million | $8.5 million |
| Market Capitalization | $50.6 million | $30 million |
Key Value Propositions
IN8bio aims to create significant value through:
- Developing next-generation therapies that exhibit stronger efficacy and fewer side effects.
- Accelerating the time-to-market for innovative treatments.
- Building a robust intellectual property portfolio around proprietary technologies.
- Establishing a sustainable business model through diversified revenue streams.
Commitment to Patients
IN8bio is committed to prioritizing patient welfare by:
- Engaging in comprehensive clinical trials to ensure safety and efficacy.
- Providing transparent communication with stakeholders regarding trial results.
- Involving patients in the drug development process to better address their needs.
Research and Development Focus
The company allocates a significant portion of its budget to research and development:
| R&D Expense Category | 2023 Estimated Allocation | 2022 Actuals |
|---|---|---|
| Gamma-delta T Cell Development | $6 million | $4 million |
| Preclinical Studies | $2 million | $1.5 million |
| Clinical Trials | $5 million | $3 million | Total R&D Expenses | $13 million | $8.5 million |
Collaborations and Partnerships
IN8bio has formed strategic alliances to enhance its capabilities:
- Collaborative ventures with major academic institutions specializing in cancer research.
- Partnerships with biotech firms to leverage complementary technologies.
- Engagement with regulatory agencies to streamline the approval process for new therapies.
Future Perspectives
Looking ahead, IN8bio aims to:
- Expand its clinical trial portfolio focusing on solid tumors.
- Increase market presence through strategic acquisitions and licensing agreements.
- Enhance patient access to therapies through innovative delivery mechanisms.
Conclusion
Through its innovative therapeutic approaches and strong commitment to research and patient welfare, IN8bio, Inc. is positioned to significantly impact cancer treatment.
How IN8bio, Inc. (INAB) Works
Business Model
Business Model
IN8bio, Inc. focuses on developing innovative cell therapies to treat various cancers. The company specializes in its proprietary platform that utilizes genetically modified T cells. IN8bio aims to enhance the immune system's ability to fight tumors.
Core Technology
IN8bio's lead product candidate, IN8-001, is under investigation for treating glioblastoma and other aggressive cancers. The therapy involves the use of γδ T cells, which are known for their ability to recognize and destroy cancer cells effectively.
Financial Overview
As of the end of Q2 2023, IN8bio reported a cash position of approximately $34 million. This cash reserves were expected to fund operations through the second half of 2024.
Recent Funding Activities
In May 2023, IN8bio completed a private placement, raising $15 million in gross proceeds. The funds are earmarked for advancing clinical trials and expanding research capabilities.
Clinical Trials
IN8bio initiated Phase 1 clinical trials for IN8-001 in the second half of 2022. The trials aim to evaluate the safety, tolerability, and efficacy of the therapy in patients with recurrent glioblastoma.
| Trial Phase | Indication | Participants | Status | Estimated Completion |
|---|---|---|---|---|
| Phase 1 | Glioblastoma | Up to 30 patients | Ongoing | Q4 2024 |
Partnerships
IN8bio has formed strategic alliances to enhance its research capabilities. Notably, collaborations with leading cancer research institutions have been critical in validating its technology.
Market Potential
The global cancer immunotherapy market is projected to reach approximately $134.4 billion by 2026, growing at a CAGR of around 12.5% from 2021 to 2026. IN8bio's unique positioning in the market aims to tap into this rapidly expanding field.
Share Performance
As of October 2023, the stock price of IN8bio, Inc. (INAB) was approximately $2.15, reflecting a market capitalization of around $39 million. The stock experienced fluctuations within the range of $1.80 to $3.00 over the year.
| Date | Price Change | Volume |
|---|---|---|
| October 1, 2023 | +5% | 150,000 |
| October 15, 2023 | -3% | 80,000 |
Future Prospects
IN8bio is poised for significant developments in the near future, with plans to advance its clinical pipeline and explore new indications for its therapies. The company is actively seeking to expand its research portfolio and partnerships to enhance its market position.
How IN8bio, Inc. (INAB) Makes Money
Revenue Streams
IN8bio, Inc., primarily derives its revenue from the development and commercialization of innovative cancer therapies, focusing on the production of cell therapies utilizing its proprietary IN8bio platform.
Key Products and Services
- IN8bio's primary focus is on its biological products, particularly its IN8-001 product candidate.
- Partnerships and collaborations with larger pharmaceutical companies.
- Clinical trial revenues and grants from research initiatives.
Financial Performance Metrics
As of the latest quarterly report in Q2 2023, IN8bio reported the following financial metrics:
| Financial Metric | Q2 2023 | Q2 2022 | % Change |
|---|---|---|---|
| Revenue | $1.2 million | $800,000 | 50% |
| Net Loss | ($3.5 million) | ($2.5 million) | 40% |
| Cash and Cash Equivalents | $15 million | $10 million | 50% |
Partnerships and Collaborations
IN8bio engages in strategic partnerships, including a collaboration with major pharmaceutical companies to enhance its research capabilities and accelerate the development of its therapies.
Research Grants and Funding
The company has secured various grants from governmental and nonprofit organizations aimed at advancing cancer research, contributing to its financial resources.
Market Opportunities
IN8bio operates in the rapidly growing cell therapy market, which is projected to reach approximately $20 billion by 2025, offering substantial growth potential for IN8bio’s revenue.
Stock Performance
As of October 2023, IN8bio's stock price is approximately $4.50 per share, with a market capitalization of about $150 million.
Future Revenue Projections
Analysts project that with successful clinical trials and potential product launches, IN8bio could achieve revenues of up to $50 million by 2025.
Expense Management
In Q2 2023, IN8bio reported operational expenses totaling $4.7 million, primarily due to R&D and administrative costs.
Investor Insights
The company raised $30 million in its latest funding round through a combination of private placements and public market offerings, enabling further advancement of its pipeline.
IN8bio, Inc. (INAB) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support